November 1 (SeeNews) - Bulgarian veterinary drug maker Biovet said on Tuesday its majority owner Huvepharma and minority shareholder Opportunity 2009 had increased their buyout offer for the remaining 9.99% stake they do not already own to 15.11 levs ($8.53/7.72 euro) per share.